Study #ALLIANCEA221208
RANDOMIZED PHASE II STUDY: CORTICOSTEROIDS + BEVACIZUMAB VS. CORTICOSTEROIDS + PLACEBO (BEST) FOR RADIONECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES
MD Anderson Study Status
Not Accepting
Treatment Agent
bevacizumab, corticosteroids
Description
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Radionecrosis, Brain Metastases
Study phase:
Phase II
Physician name:
Barbara O'Brien
Department:
Neuro-Oncology
For general questions about clinical trials:
1-855-508-2908
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.